Committed to Research
Most recently our flagship products were utilized in a groundbreaking medical study published in the International Journal of Clinical Medicine. This study marks a significant milestone in the treatment of Peripheral Neuropathy and reaffirms Bedrock’s commitment to advancing medical knowledge and improving patient care.
Titled “Treatment of Peripheral Neuropathy“, the study was conducted by a group of esteemed researchers, including the University of California Department of Medicine and the Institute for Molecular Medicine, aimed to investigate and revolutionize the current approach to medical treatment for peripheral neuropathy. The research involved a rigorous analysis of data from an extensive patient group, leading to exciting and unprecedented findings.
The study’s key findings unveiled innovative treatment strategies that have the potential to transform the lives of patients worldwide. The combination therapy using the Bedrock Legacy LightPad, Extracorporeal Shockwave Therapy, Platelet Rich Plasma and the Bedrock nerve support supplement were proven effective in treating peripheral neuropathy in the clinical trial.
This study represents a major breakthrough for the non-pharmacological treatment for peripheral neuropathy. Bedrock Bioscience is known for its commitment to scientific excellence and has a history of pioneering medical breakthroughs.
Bedrock Bioscience is constantly improving our products in conjunction with current technological advancements. This allows us to provide the most up to date and extensive suite of product options.
All Bedrock Bioscience lights are made in an FDA registered facility.